Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BLGO · OTC · United States · Chemicals & Allied Products
In shortBIOLARGO, INC. is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−56.3% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -191.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -151.7% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -182.7% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -191.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.01× | 18/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.51× | 83/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -27.51× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -74.61 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -106.9% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 76.7% | 0/100 |
| Operating margin volatility | 104.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 9.7% | 70/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2.5 | 5.9 | 12 | 18 | 7.8 |
| Cost of revenue | 1.4 | 3 | 6.1 | 9.9 | 4.4 |
| Gross profit | 1.1 | 2.9 | 6.2 | 7.9 | 3.4 |
| Research & development | 1.4 | 1.3 | 2.3 | 2.9 | 2.6 |
| Selling, general & admin | 6.2 | 6.7 | 8.1 | 9.3 | 12 |
| Operating income | (6.8) | (5.4) | (4.6) | (4.3) | (15) |
| Interest expense | 0.2 | 0.1 | 0.1 | 0.1 | 0.5 |
| Pre-tax income | – | – | – | (4.3) | (15) |
| Income tax | – | – | 0 | 0 | – |
| Net income | (7.1) | (4.5) | (3.5) | (2.4) | (12) |
| Diluted EPS | −$0.03 | – | – | – | – |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of BIOLARGO, INC. are included in the Investor plan. Try free for 7 days →
−74.61 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
1/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 14, 2026